TAS-102 With Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer

Rectal Adenocarcinoma Clinical Trial

Official title:

Phase 1b Study to Assess the Safety of Neoadjuvant TAS-102 (Trifluridine/Tipiracil) With Concurrent Radiation in Previously Untreated Resectable Stage II and Stage III Rectal Cancer (FIERCE)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04104139
• Other study ID #: STUDY00019576
• Secondary ID: NCI-2019-06387SO
• Status: Recruiting
• Phase: Phase 1
• Start date: December 11, 2019
• Est. completion date: December 31, 2024

Study information

• Verified date: February 2024
• Source: OHSU Knight Cancer Institute
• Contact: OHSU Knight Cancer Clinical Trials Hotline
• Phone: 503-494-1080
• Email: trials[@]ohsu.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This phase 1b trial studies the side effects and best dose of TAS-102 when given together with radiation therapy in treating patients with stage II-III rectal cancer that has not been treated and can be removed by surgery (resectable). Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. This study is being done to find out the safest dose of TAS-102 that can be used with radiation treatment for rectal cancer.

Description:

PRIMARY OBJECTIVE:

I. To determine the recommended phase 2 dose of trifluridine and tipiracil hydrochloride (TAS-102) per the proportion of grade 3 or higher adverse events during chemo-radiation therapy (CRT) with concurrent TAS-102 at the maximum tolerated dose by allowing no more than 30% grade 3 or higher adverse events.

SECONDARY OBJECTIVES:

I. Evaluate safety of participants treated with TAS-102 during radiation therapy (RT).

II. Evaluate treatment emergent adverse events (TEAEs) attributable to TAS-102 with RT during fluorouracil/leucovorin calcium/oxaliplatin (FOLFOX) or capecitabine/oxaliplatin (CAPOX) treatment.

EXPLORATORY OBJECTIVES:

I. To preliminary assess the rates of complete clinical response (cCR) by magnetic resonance imaging (MRI) and by endoscopy after TAS-102 with concurrent CRT.

II. To preliminary assess the rates of cCR by MRI and by endoscopy after treatment with FOLFOX.

III. To preliminary assess the rates of pCR after standard total mesorectal excision (TME).

OUTLINE: This is dose-escalation study of TAS-102.

Patients receive TAS-102 orally (PO) twice daily (BID) Monday-Friday on weeks 1, 3, and 5. Patients also undergo intensity modulated radiotherapy (IMRT) or 3-dimensional conformal radiotherapy (3D-CRT) 5 days per week on weeks 1-5. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care FOLFOX or CAPOX.

After completion of study treatment, patients are followed for up to a total of 16 weeks (3 months) from end of FOLFOX or CAPOX treatment until rectal cancer surgery or death, whichever occurs first. Participants that opt for a non-surgical option at the end of chemotherapy may be followed for a longer period of time.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 18
• Est. completion date: December 31, 2024
• Est. primary completion date: June 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• All races and ethnic groups will be included

• Histologically confirmed diagnosis of adenocarcinoma of the rectum

• Clinical stage II (T3-4aN0M0) and stage III (T1-4aN1+M0) based on MRI

• Resectable primary rectal tumor at baseline

• No evidence of distant metastases

• No prior pelvic radiation therapy

• No prior chemotherapy or surgery for rectal cancer

• No active infections requiring systemic antibiotic treatment (oral antibiotics are acceptable at the discretion of the treating physician)

• Eastern Cooperative Oncology Group (ECOG) performance status 0-1

• Leukocytes >= 3,000/uL

• Absolute neutrophil count >= 1,500/uL

• Hemoglobin >= 9.0 gm/dL

• Platelets >= 100,000/uL

• Total bilirubin within normal institutional limits

• Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x institutional upper limit of normal (ULN)

• Creatinine within normal institutional limits, OR creatinine clearance >= 60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal

• Female participants of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. A female of childbearing potential is defined of one who is biologically capable of becoming pregnant. Reliable contraception should be used starting from trial screening and must be continued throughout the study

• Females of childbearing potential must agree to use effective contraceptive method starting with the first dose of study therapy through 6 months after the last dose of study therapy

• Male participants must agree to use an effective method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy

• Participants must read, have the ability to understand, agree to, and sign a statement of Informed Consent prior to participation in this study

• Participants must, as part of their planned treatment per institutional guidelines, be:

• Scheduled to receive preoperative FOLFOX or CAPOX chemotherapy, which requires a central venous access device for administration

• Able to undergo planned TME of the rectal tumor per institutional standards

Exclusion Criteria:

• Recurrent rectal cancer

• Primary unresectable rectal cancer. A tumor is considered unresectable when invading adjacent organs (T4b disease) and an en bloc resection will not achieve negative margins. Rectal cancer presenting with concurrent or overlapping sites in the colon is eligible if these sites could be removed with surgery

• Distant nodal disease (retroperitoneal nodes), or any metastatic disease by computed tomography (CT) or positron emission tomography (PET)

• Creatinine > 1.5 x ULN

• History of peripheral neuropathy > grade 2

• History of malabsorption syndromes or inflammatory bowel disease

• Use of immunosuppressive or myelosuppressive medications including but not limited to adalimumab, azathioprine, BCG, clozapine, cyclosporine, deferiprone, etanercept, fingolimod, hydroxyurea, interferon, leflunomide, methotrexate, mycophenolate, natalizumab, pimecrolimus, rituximab, sirolimus, and tacrolimus

• Inability to take oral medications

• Participants who received prior pelvic radiotherapy

• Use of induction chemotherapy prior to chemo-radiation of rectal cancer

• Use of other chemotherapy regimens other than FOLFOX or CAPOX

• Participants who are unable to undergo an MRI

• Participants who are unable to undergo TME

• Refusal of standard-of-care TME of the rectal tumor if there is persistent disease after neoadjuvant treatment

• Participants with a history of any arterial thrombotic event within the past 6 months, including angina (stable or unstable), myocardial infarction (MI), transient ischemic attack (TIA), or cerebrovascular accident (CVA)

• Participants with a recent history of venous thrombotic episodes such as deep venous thrombosis and pulmonary embolism within the past 3 months. If these episodes occurred more than three months prior to enrollment, they may be considered for protocol participation, provided they are on stable doses of anticoagulant therapy. Similarly, participants who are anticoagulated for atrial fibrillation or other conditions may participate, provided they are on stable doses of anticoagulant therapy

• Febrile illness within 7 days of study enrollment

• History of allergic reactions attributed to compounds of similar chemical or biologic composition to TAS-102 or other agents used in this study

• Other anticancer or experimental therapy. No other experimental therapies including for other disease indications are allowed while the participant is receiving study treatment

• Women who are pregnant or breast-feeding

• Participants with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgment, would make them inappropriate candidates for entry into this study

• Participants with a history of a prior malignancy within the past 5 years, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer

Related Conditions & MeSH terms

• Rectal Adenocarcinoma
• Rectal Neoplasms
• Stage IIA Rectal Cancer AJCC v8
• Stage IIB Rectal Cancer AJCC v8
• Stage III Rectal Cancer AJCC v8
• Stage IIIA Rectal Cancer AJCC v8
• Stage IIIB Rectal Cancer AJCC v8
• Stage IIIC Rectal Cancer AJCC v8

Intervention

Radiation:
• 3-Dimensional Conformal Radiation Therapy
Undergo 3D-CRT
• Intensity-Modulated Radiation Therapy
Undergo IMRT

Drug:
• Trifluridine and Tipiracil Hydrochloride
Given PO

Locations

Country	Name	City	State
United States	OHSU Knight Cancer Institute	Portland	Oregon

Sponsors (3)

Lead Sponsor	Collaborator
OHSU Knight Cancer Institute	Oregon Health and Science University, Taiho Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Rate of complete response (CR) by magnetic resonance imaging (MRI) after chemo-radiation therapy (CRT)	MRI report after CRT will be collected from medical records. Discrepancies will be resolved with the diagnostic radiology investigators of the research team. Complete response based on MRI will be tabulated as proportions and analyzed descriptively using the CRT analysis sets.	Prior to starting FOLFOX or CAPOX regimen (up to 8 weeks)
Other	Rate of CR by endoscopic exam after CRT	Endoscopic exam report after CRT will be collected from medical records (as available). Discrepancies will be resolved with the surgical oncology investigators of the research team. Complete response based on endoscopic exam will be tabulated as proportions and analyzed descriptively using the CRT analysis sets.	Prior to starting FOLFOX or CAPOX regimen (up to 8 weeks)
Other	Rate of clinical complete response (cCR) by MRI and endoscopic response after CRT	cCR requires CR for MRI and CR for endoscopic responses. The number of cCR after CRT will be tabulated as proportions using the CRT analysis sets, respectively.	Prior to starting FOLFOX or CAPOX regimen (up to 8 weeks)
Other	Rate of CR by MRI after CRT and FOLFOX or CAPOX	MRI report after CRT + FOLFOX or CAPOX will be collected from medical records. Discrepancies will be resolved with the diagnostic radiology investigators of the research team. Complete response based on MRI will be tabulated as proportions and analyzed descriptively using the CRT and the FOLFOX/CAPOX analysis sets, respectively.	At end of chemotherapy visit (up to 21 weeks)
Other	Rate of CR by endoscopic exam after CRT and FOLFOX or CAPOX	Endoscopic exam report after CRT + FOLFOX or CAPOX will be collected from medical records (as available). Discrepancies will be resolved with the surgical oncology investigators of the research team. Complete response based on endoscopic exam will be tabulated as proportions and analyzed descriptively using the CRT and the FOLFOX/CAPOX analysis sets, respectively.	At end of chemotherapy visit (up to 21 weeks)
Other	Rate of cCR by MRI and endoscopic response after CRT and FOLFOX or CAPOX	cCR requires CR for MRI and CR for endoscopic responses. The number of cCR after CRT and after CRT + FOLFOX or CAPOX will be tabulated as proportions using the CRT and the FOLFOX/CAPOX analysis sets, respectively.	At end of chemotherapy visit (up to 21 weeks)
Other	Rate of pathologic complete response after standard total mesorectal excision (TME)	Pathology report after standard TME will be collected from medical records. Discrepancies will be resolved with the surgical oncology and pathology investigators of the research team. Complete response based on pathology will be tabulated as proportions and analyzed descriptively using the TME population.	At resection (up to 29 weeks)
Primary	Proportion of dose limiting toxicity (DLT)s for TAS-102 at the maximum tolerated dose (MTD)	Will be assessed through the Bayesian optimal interval design and will be determined by the proportion of grade 3 or higher adverse events during chemo-radiation therapy (CRT) with TAS-102 at the MTD by allowing no more than 30% DLT. The proportion will be descriptively noted.	Up to end of week 8, or start of fluorouracil/leucovorin calcium/oxaliplatin (FOLFOX) or capecitabine/oxaliplatin (CAPOX) chemotherapy, whichever occurs first
Secondary	Incidence of adverse events (AEs) (all grade) for TAS-102 concurrent with radiation therapy (RT)	Descriptive statistics of safety will be presented using National cancer Institute Common Terminology Criteria for Adverse Events version 5.0., with AEs tabulated by the MedDRA preferred term and system organ class. The incidence of AEs (all grades) for TAS-102 with concurrent RT will be assessed using the CRT analysis set.	Up to start of FOLFOX or CAPOX (up to 8 weeks)
Secondary	Incidence of grade 3 or higher treatment emergent adverse events (TEAEs) during FOLFOX or CAPOX treatment	The incidence of grade 3 or higher TEAEs during FOLFOX or CAPOX chemotherapy will be assessed using the FOLFOX/CAPOX analysis set.	Up to end of FOLFOX or CAPOX (up to 16 weeks)